The pathogenic fungus Cryptococcus neoformans expresses two functional GDP-mannose transporters with distinct expression patterns and roles in capsule synthesis

Tricia R. Cottrell  
*Washington University School of Medicine in St. Louis*

Cara L. Griffith  
*Washington University School of Medicine in St. Louis*

Hong Liu  
*Washington University School of Medicine in St. Louis*

Ashley A. Nenninger  
*Washington University School of Medicine in St. Louis*

Tamara L. Doering  
*Washington University School of Medicine in St. Louis*

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
The Pathogenic Fungus Cryptococcus neoformans Expresses Two Functional GDP-Mannose Transporters with Distinct Expression Patterns and Roles in Capsule Synthesis

Tricia R. Cottrell, Cara L. Griffith, Hong Liu, Ashley A. Nenninger and Tamara L. Doering


Updated information and services can be found at: http://ec.asm.org/content/6/5/776

These include:

This article cites 61 articles, 34 of which can be accessed free at: http://ec.asm.org/content/6/5/776#ref-list-1

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
The Pathogenic Fungus *Cryptococcus neoformans* Expresses Two Functional GDP-Mannose Transporters with Distinct Expression Patterns and Roles in Capsule Synthesis

Tricia R. Cottrell,†‡ Cara L. Griffith,‡ Hong Liu, Ashley A. Nenninger, and Tamara L. Doering*

Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri

Received 12 January 2007/Accepted 27 February 2007

*Cryptococcus neoformans* is a fungal pathogen that is responsible for life-threatening disease, particularly in the context of compromised immunity. This organism makes extensive use of mannose in constructing its cell wall, glycoproteins, and glycolipids. Mannose also comprises up to two-thirds of the main cryptococcal virulence factor, a polysaccharide capsule that surrounds the cell. The glycosyltransfer reactions that generate cellular carbohydrate structures usually require activated donors such as nucleotide sugars. GDP-mannose, the mannose donor, is produced in the cytosol by the sequential actions of phosphomannose isomerase, phosphomannomutase, and GDP-mannose pyrophosphorylase. However, most mannose-containing glycoconjugates are synthesized within intracellular organelles. This topological separation necessitates a specific transport mechanism to move this key precursor across biological membranes to the appropriate site for biosynthetic reactions. We have discovered two GDP-mannose transporters in *C. neoformans*, in contrast to the single such protein reported previously for other fungi. Biochemical studies of each protein expressed in *Saccharomyces cerevisiae* show that both are functional, with similar kinetics and substrate specificities. Microarray experiments indicate that the two proteins Gmt1 and Gmt2 are transcribed with distinct patterns of expression in response to variations in growth conditions. Additionally, deletion of the *GMT1* gene yields cells with small capsules and a defect in capsule induction, while deletion of *GMT2* does not alter the capsule. We suggest that *C. neoformans* produces two GDP-mannose transporters to satisfy its enormous need for mannose utilization in glycan synthesis. Furthermore, we propose that the two proteins have distinct biological roles. This is supported by the different expression patterns of *GMT1* and *GMT2* in response to environmental stimuli and the dissimilar phenotypes that result when each gene is deleted.

Mannose is a key component of glycoconjugates in all eukaryotes but plays a special role in yeast, where it dominates the carbohydrate landscape. In contrast to mammals, where mannose is one of an array of moieties used to generate glycan structures, a substantially more restricted range of sugars is used in those fungi that have been examined in detail (19). The best-studied yeast, *Saccharomyces cerevisiae*, uses only glucose, N-acetylglucosamine, and mannose to build the vast majority of its protein- and lipid-linked carbohydrate structures, and mannose is by far the most abundant sugar in these two classes of biosynthetic products. For example, N-linked carbohydrate chains in this yeast are composed of a core of two N-acetylglucosamine and eight mannose residues, which is further extended with up to hundreds of additional mannoses (19). These mannose chains comprise the mannan that is an important component of the yeast cell wall (28). Similarly, O-linked carbohydrate chains in *S. cerevisiae* contain only mannose, ranging from one to five residues, and sphingolipids contain just mannose and inositol (16).

To generate the extensive array of mannosylated compounds described above, yeasts must supply appropriate mannose donor molecules to the enzymes that mediate their synthesis. The simplest donor is the nucleotide sugar GDP-mannose (GDP-Man), described by Cabib and Leloir in 1954 (11). This compound is generated in the cytosol by the sequential actions of phosphomannomannose isomerase, phosphomannomutase, and GDP-Man pyrophosphorylase (57). Some GDP-Man is consumed at the cytosolic face of the endoplasmic reticulum by incorporation into a dolichol phosphomannose lipid that is then flipped into that organelle and used to synthesize N-linked core oligosaccharides and glycosylphosphatidylinositol anchors (23). Much of it, however, is used within the Golgi complex for the synthesis of glycolipids and O-linked glycans (59) and for the outer-chain elaboration of core N-linked structures (14, 36). The location of these synthetic processes leads to a topological problem, which is solved in yeast by the presence of specific Golgi apparatus-localized GDP-Man transporters (1, 15, 38, 39). These proteins import the highly charged mannose precursor from the cytosol into the Golgi apparatus, operating against a concentration gradient via an antiport mechanism that exchanges GDP-Man for GMP. Notably, because mammalian cells do not perform mannosylation in the Golgi apparatus, they have no GDP-Man transporters, although these transporters have been described for plants (8, 22) and for the protozoan parasite *Leishmania donovani* (33).

Our studies focus on the fungal pathogen *Cryptococcus neoformans*. This organism causes serious disease and life-threatening meningitis, especially in the context of compromised
immunity. In addition to using mannose for the synthesis of protein- and lipid-linked structures in the manner described above, *C. neoformans* incorporates this sugar into an extensive polysaccharide capsule that surrounds the cell wall (reviewed in reference 10). The capsule, which is required for virulence, is composed of two polysaccharides. The larger polymer, glucuronoxylomannan (GXM), has a repeating structure with monosaccharide branches of xylose and glucononic acid linked to a mannose backbone (13). Mutants that do not synthesize GXM do not cause disease in experimental animal models (12). The second polymer, galactoxylomannan, has a galactose backbone, with side chains composed of galactose, xylose, and mannose (56); its biological function is less well understood.

We have recently found material that reacts with anti-GXM antibodies in post-Golgi exocytic vesicles in *C. neoformans* (60). This finding indicates that capsule components are made within secretory organelles and are then packaged into transport vesicles for release at the cell surface when those vesicles fuse with the plasma membrane. In this scenario, capsule synthesis, like the other luminal processes mentioned above, will rely on GDP-Man import via a nucleotide sugar transporter. Mannose comprises one- to two-thirds of all sugar residues in the capsule, depending on the serotype of *C. neoformans*, so the demands for this transport will be high.

Almost 20 years ago, Hirschberg and coworkers demonstrated GDP-Man transport in yeast by using a mixed vesicle preparation from *S. cerevisiae* (3). A putative GDP-Man transporter was not identified until almost 10 years later, however, when Turco, Beverley, and colleagues showed that microsomes isolated from wild-type *L. donovani* were able to import this compound, while cells mutated in the *LPG2* gene could not. The mutant cells lost the ability to transport GDP-Man but not UDP-galactose, and the defect was corrected by the reintroduction of the gene (33). Although this initial study did not prove that Lpg2 itself was the transport protein, subsequent work showed that Lpg2 could mediate GDP-Man transport activity when expressed in mammalian cells (25), and recent reconstitution experiments proved that this protein is indeed the transporter (51). Interestingly, Lpg2 acts as a hexameric complex and is multifunctional, with the ability to transport GDP-Man, GDP-arabinose, and GDP-fucose (25). The *Leishmania* parasite uses GDP-Man in the synthesis of its surface coat and related molecules. *Lpg2* mutants lack normal forms of these molecules but still demonstrate normal N-glycosylation, glycosylphosphatidylinositol anchors, glycolipids, and growth (35).

Close to the time that Lpg2 activity was described, Dean and colleagues used a permeabilized cell assay to demonstrate GDP-Man transport in *S. cerevisiae* and to implicate the yeast protein Vrg4 in this process (15). Those authors had previously shown that Vrg4 was required for N-linked mannosylation, secretion, and protein sorting (44); based on in vitro transport studies of mutant and wild-type strains, and the protein’s homology to other known nucleotide sugar transporters, they suggested that it was the transporter itself. Subsequent work on Vrg4 defined a conserved motif required for substrate binding, showed that the protein occurred as a dimer and was localized to the Golgi apparatus, and identified regions responsible for dimerization, stability, and trafficking (1, 2, 17, 18). Unlike the case with the *Leishmania* Lpg2 protein, Vrg4 is essential for viability in yeast (44).

Although Vrg4 and Lpg2 have been the most thoroughly examined, several other GDP-Man transporters have been identified in the decade since these two proteins were first implicated in this process. These transporters have been identified by sequence homology and by their ability to complement a partial mutant in *VRG4*, vrg4-2, but they have not been characterized biochemically. In the fungal pathogen *Candida albicans*, the single Vrg4 homolog is Golgi apparatus localized and essential for viability, similar to *S. cerevisiae* Vrg4; a partial loss of function of this protein led to mannosylation defects that caused cell wall-associated phenotypes (39). In a related pathogen, *Candida glabrata*, deletion of the single *VRG4* homolog was also lethal (38). Additional studies of Vrg4 have focused on its utility as a marker of the Golgi apparatus in fungi in both *S. cerevisiae* (32) and *Pichia pastoris* (4).

We have investigated GDP-Man transport in *C. neoformans*, motivated by the central role of mannose in the major cryptococcal virulence factor, the capsule, and by the fact that GDP-Man transport is a fungus-specific activity and therefore an intriguing potential drug target. We have discovered that *C. neoformans* encodes and expresses two functional transporters of GDP-Man, a unique finding among fungi. Direct assays of activity in permeabilized cells show that the two proteins have similar biochemical properties. However, transcriptional analysis indicates that they are not coordinately regulated and are therefore likely to play distinct roles in cryptococcal biology. Furthermore, deletion of the two genes results in contrasting capsule phenotypes: *gmt1* mutants have reduced capsule size and the ability to induce capsule, while *gmt2* cells appear to have wild-type capsules.

**MATERIALS AND METHODS**

**Strains and growth conditions.** *C. neoformans* strains used were serotype D strains JEC21 (MATa, from Jennifer Lodge, Saint Louis University Medical Center) and JEC43 (MATa ura5, from Joe Heitman, Duke University Medical Center), and serotype A wild-type strain H99 (MATa, from Gary Cox, Duke University Medical Center). *S. cerevisiae* strains used were NDY5 (MATa ura3-52 leu2-112 1-1 vr14-2) (15) and JPY26 3d (MATa ura3-52 leu2-112 ade2-101 vr14-2 rpmI) (15), provided by Neta Dean (State University of New York at Stony Brook). All cells were grown with continuous shaking at the temperatures indicated in the text in the following media: YPD (1% Bacto yeast extract, 2% dextrose, 2% sodium acetate, 2% sodium succinate, or 1 mM H2O2; YNB medium (DMEM); Littman’s medium (as described in reference 29) with either 0.01 or 1 mg/ml thiamine; phosphate-buffered saline (PBS); PBS with 10% fetal bovine serum (as described in reference 62); minimal medium with 2% glucose but lacking uracil (as described in reference 6); or minimal medium lacking leucine and supplemented with 0.5 M KCl.

**Sequences and alignment.** The *S. cerevisiae* Vrg4 protein sequence (GenBank accession number NP_011290) was BLAST searched against the *C. neoformans* serotype D database compiled by The Institute for Genome Research (http://www.tigr.org/tdb/etl/c2kl/cma1/cma1). Two closely related sequences were identified and assessed using the Align X program within Vector NTI (Invitrogen, Carlsbad, CA). The first gene (TIGR accession number CNF12620 and GenBank accession number AAY85624) encoded a predicted protein that is 49% identical and 65% similar to Vrg4, which we termed *Gmt1* for GDP-Man transporter 1. The second gene (TIGR accession number CNG01600 and GenBank accession number AA9R6298) encoded a protein with 46% identity and 63% similarity to Vrg4 and was named *Gmt2*.

**Gene cloning and expression in S. cerevisiae.** Yeast episomal plasmids containing a 2-μm origin of replication, the GAP (glyceraldehyde-3-phosphate dehydrogenase) promoter, and the URA3 marker, without or with the *VRG4* se-
sequence (YEp352GAP and YEp352GAP-YFRG4, respectively), were obtained from Neta Dean. We used standard PCR techniques and primers 401 to 404 in Table 1 to amplify GMT1 and GMT2 from JEC43 cDNA (prepared as described in reference 47) and incorporate flanking restriction sites (5′/H11032 EcoRI and 3′/H11032 KpnI). The resulting segments were inserted between the corresponding sites of YEp352GAP, and the constructs were transformed into NDY5 cells by electroporation. The resulting strains were primed by the insertion of YEp352GAP, and the constructs were transformed into NDY5 cells by electroporation.

Reverse transcriptase PCR. For assays, semi-intact cells were thawed quickly and washed three times in 1 ml of ice-cold buffer H (20 mM HEPES [pH 6.8], 150 mM potassium acetate, 250 mM sorbitol, 5 mM magnesium acetate). Standard reaction mixtures included 50 nCi of GDP-3Hmannose (GDP-3HMan) (20 Ci/mmol; American Radiolabeled Corporation, St. Louis, MO), 3 μM GDP-Man, and 30 μg yeast protein. Reverse transcriptase reactions were performed with 10 μg of total RNA, oligo(dT) primers, and SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s instructions, and treated with DNase I (Invitrogen). Reverse transcriptase reactions were performed with 10 μg of total RNA, oligo(dT) primers, and SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer’s instructions. Real-time PCR used EZ RT-PCR Core Reagents and probes that were designed using Applied Biosystems PRIMEREXPRESS software, both obtained from Applied Biosystems. The probes and primers used (from Invitrogen) are listed in Table 2 as reference figures 415 to 423 in Table 1. Experiments were performed using an ABI Prism 7000 instrument according to the manufacturer’s instructions, with ACT1 expression serving for normalization between conditions. The amplification program consisted of 1 min at 60°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C alternating with 1 min at 60°C. Each PCR experiment included serial dilutions of known concentrations of each cDNA. 

**TABLE 1. Primers and probes**

<table>
<thead>
<tr>
<th>Primer or probe</th>
<th>Description</th>
<th>Sequence (5′-3′)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expression</td>
<td>GMT1</td>
<td>ATCGATGAAATTCCCACTGAGGAAATAC</td>
</tr>
<tr>
<td></td>
<td>GMT1 reverse</td>
<td>ATCGATGATCCGCCTGGTTAGTCTTT</td>
</tr>
<tr>
<td></td>
<td>GMT2</td>
<td>GGAATTCCATGCTTCCTACCC</td>
</tr>
<tr>
<td></td>
<td>GMT2 reverse</td>
<td>GGGGTACCTGATACGCGCTTTCTCCT</td>
</tr>
<tr>
<td></td>
<td>LEU2</td>
<td>ATCGATGCGCCTATACCATCAATTATTT</td>
</tr>
<tr>
<td></td>
<td>LEU2 reverse</td>
<td>ATCGATGCGGCACATACATCTGAATTATATT</td>
</tr>
<tr>
<td>Gene deletion</td>
<td>GMT1</td>
<td>AGGGCTGTCTTTGACAGAGTTTGA</td>
</tr>
<tr>
<td></td>
<td>GMT1 reverse</td>
<td>GACATCTCACTGACGGCCTCTCCTGTA</td>
</tr>
<tr>
<td></td>
<td>GMT2</td>
<td>AGGCTCTTGGCCCCCTTTCTCCTCGT</td>
</tr>
<tr>
<td></td>
<td>GMT2 reverse</td>
<td>TCCAGATCTTGCTGGTCTAGGCTTA</td>
</tr>
<tr>
<td></td>
<td>Genetin</td>
<td>CTAGCTAGCACCTTCTATTTGAGGCTG</td>
</tr>
<tr>
<td></td>
<td>Genetin reverse</td>
<td>TGGGACACAGATGATACCGGCG</td>
</tr>
<tr>
<td></td>
<td>Nourseothricin</td>
<td>GCCAGTGAAATTGTAATAGACTAC</td>
</tr>
<tr>
<td></td>
<td>Nourseothricin reverse</td>
<td>GAAGATCTCCTCTGAAGACTAGTGGATCCC</td>
</tr>
<tr>
<td>Reverse transcriptase PCR</td>
<td>ACT1</td>
<td>CTGCACAAACTGCGAGCAGCAT</td>
</tr>
<tr>
<td></td>
<td>ACT1 reverse</td>
<td>CGACAGCGAGGCTATCTGGTGAAG</td>
</tr>
<tr>
<td></td>
<td>ACT1 probe</td>
<td>FAM-AGAAAGATCCTGGACACCATAC-MGBNFQ</td>
</tr>
<tr>
<td></td>
<td>GMT1</td>
<td>GGAATTCCATGCTTCCTACCC</td>
</tr>
<tr>
<td></td>
<td>GMT1 reverse</td>
<td>CACCAGGCAACACACAA</td>
</tr>
<tr>
<td></td>
<td>GMT2</td>
<td>FAM-CATCTCGGCCCCATGC-MGBNFQ</td>
</tr>
<tr>
<td></td>
<td>GMT2 reverse</td>
<td>GCAAGAAGAGGAGGATAGTC</td>
</tr>
<tr>
<td></td>
<td>GMT2 revers</td>
<td>CATGAGCTTGAAGTCTCCAGTA</td>
</tr>
<tr>
<td></td>
<td>GMT2 probe</td>
<td>FAM-CCCGAGACACTACTMGBNFQ</td>
</tr>
</tbody>
</table>

* All gene sequences are from C. neoformans except for LEU2, which is from S. cerevisiae. Sequences that introduce restriction sites are italicized.

b FAM, 6-carboxyfluorescein reporter dye; MGBNFQ, molecular groove binding nonfluorescent quencher.
RNA for microarray analysis. Total RNA was prepared from 100-ml cultures of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were sedimented (5 min, 6,000 × g at 4°C), washed with 50 ml diethyl pyrocarbonate-treated double-distilled water, and sedimented again, and the pellet was frozen in a dry ice–methanol bath and lyophilized overnight. Each dried cell pellet was vigorously vortex mixed with 3 ml of 0.5-mm glass beads (BioSpec, Bartlesville, OK) for 15 min and then combined with 8 ml RT TRIzol reagent (Invitrogen) and vortex mixed for an additional 1 min. Tubes were left at RT for 5 min, mixed with 1.6 ml of chloroform, shaken gently, and incubated for 3 min at RT. The mixture was transferred to a fresh tube, covered with parafilm, and centrifuged (15 min at 7,600 × g at RT). The upper aqueous phase was removed to a fresh tube, slowly mixed with 1 volume of 70% ethanol, and applied to an RNase Maxi column, which was centrifuged in a swinging-bucket rotor (5 min at 3,000 × g at RT). The flowthrough fraction was reapplied to the column and eluted as described above, and the column was then washed, treated with RNase-Free DNase (QIAGEN), washed, and eluted according to the manufacturer’s instructions. Eluted RNA was precipitated with a 1/10 volume of 3 M sodium acetate and 2.5 volumes of absolute ethanol on dry ice, and the pellet was recovered by centrifugation (15 min at 8,000 × g at 4°C), washed with 75% ethanol, and allowed to air dry before resuspension in formamide at 4 mg/ml and storage at −20°C. For analysis, RNA was precipitated and resuspended in diethyl pyrocarbonate-treated water, and the concentration and purity were determined from absorbance readings at 260 nm and 280 nm. Total RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies) according to the manufacturer’s recommendations.

We generated a reference pool of RNA by combining 67 independent RNA preparations from 27 combinations of strains and growth conditions. The cells used for RNA preparation were JEC21 grown in YPD (at 25°C, 30°C, and 37°C), YNB plus glucose (at 25°C, 30°C, 35°C, and 37°C), YNB plus acetate (at 30°C and 37°C), YNB plus succinate (at 30°C), YNB plus NaNO$_3$ (at 25°C), YNB plus H$_2$O$_2$ (at 25°C), LIM with and without BPDS (at 37°C), DMEM (grown in room air or 5% CO$_2$ at 37°C), Littman’s medium (both thiamine concentrations plus glucose (at 30°C) and JEC43, JEC43 with pCMT1/ADE2i (52), JEC43 with pCMT1/ADE2i, and pGEM-ADE2i (52), grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA at RT, and 0.2 μl of the indicated strain grown to an OD$_{600}$ value of 1 to 2 units. Cells were grown at 30°C in minimal medium lacking uracil. The pooled RNA was carried out using the complementary capture reagents provided in the 3DNA...
RESULTS

Motivated by the importance of mannose to cryptococcal biology and virulence, we sought the \textit{C. neoformans} homolog of the well-characterized \textit{S. cerevisiae} GDP-Man transporter Vrg4. Unexpectedly, database searches of the cryptococcal serotype D genome (http://www.tigr.org/tdb/e2k1/cna1/) (31) yielded two closely related sequences, with GenBank accession numbers AAY85624 and AAR96298. We named these sequences \textit{GMT1} and \textit{GMT2}, respectively. \textit{GMT1} encodes a 397-amino-acid protein with 49\% identity to Vrg4 (Fig. 1a), while \textit{GMT2} encodes a 420-amino-acid protein that is 46\% identical to Vrg4 and 63\% identical to the protein encoded by \textit{GMT1}.

Aligning by the positions of the most highly conserved sequences, the cryptococcal proteins are extended at the N terminus compared to \textit{S. cerevisiae} Vrg4 (by 40 amino acids for Gmt1 and 59 amino acids for Gmt2) and contain two additional small peptide insertions (four to eight residues) in the central region of the protein as well as nine additional residues at the C terminus. A conserved “GALNK” motif that has been identified in Vrg4 as required for nucleotide sugar binding (17) is present in both of the predicted cryptococcal proteins (Fig. 1b), and the C-terminal region of each bears multiple basic residues (Fig. 1c), a feature that has been implicated in the intracellular trafficking of related proteins (2).

We next tested whether the putative cryptococcal GDP-Man transporters could functionally complement \textit{S. cerevisiae} strain \textit{vrg4-2}. This strain bears a point mutation in the GALNK motif (Fig. 1b) and is deficient in GDP-Man transport. Although these cells perform enough transport to survive, they are sensitive to the aminoglycoside hygromycin B and to osmotic stress, and they display defects in Golgi apparatus glycosylation (44). We amplified \textit{GMT1} and \textit{GMT2} from cDNA of \textit{C. neoformans} and cloned each gene into a yeast episomal plasmid under the control of the GAP promoter to drive strong constitutive levels of expression. We then expressed each construct in \textit{vrg4-2} cells. As shown in Fig. 2, each cryptococcal gene complemented the \textit{vrg4-2} sensitivity to hygromycin, while plasmid alone did not. This proves that both cryptococcal proteins can function as GDP-Man transporters.

To measure the levels of activity of the two cryptococcal proteins directly, we expressed each one heterologously in \textit{S. cerevisiae} strain \textit{vrg4-2} cells. As shown in Fig. 2, each cryptococcal gene complemented the \textit{vrg4-2} sensitivity to hygromycin, while plasmid alone did not. This proves that both cryptococcal proteins can function as GDP-Man transporters.
and assayed GDP-[3H]Man transport in vitro, a cross-species approach that has been effective for studies of nucleotide sugar transporters from mammals and plants (7, 21, 40, 50, 54). To do this, we expressed each protein in vrg4-2 mutant cells that were also mutated in the gene encoding dolichol phosphomannose synthase (DPM1) (42, 43). This mutation serves to reduce background signal from radiolabeled mannose that becomes membrane associated independent of GDP-Man translocation into the Golgi apparatus (see above). We then measured GDP-[3H]Man transport using dpm1 vrg4-2 mutant cells with vector alone or the same cells expressing Gmt1, Gmt2, or Vrg4. As shown in Fig. 3, the two cryptococcal proteins showed levels of activity that were comparable to each other and to that of Vrg4 itself. Uptake activity in vitro was linear for the first 6 min (Fig. 3, inset), comparable to data from previous reports. The activity of each transporter was dependent on protein concentration (Fig. 4a), and substrate titration showed saturable uptake (shown for Gmt1 in Fig. 4b), with \( K_m \) values of 8.3 \( \mu M \) for Gmt1 and 3.8 \( \mu M \) for Gmt2 (calculated from double-reciprocal plots) (shown for Gmt1 in Fig. 4b, inset). These are comparable to the \( K_m \) of 6.6 \( \mu M \) determined for GDP-Man transport by reconstituted *Leishmania* Lpg2 (51) and to typical \( K_m \) values for other nucleotide sugar transporters (between 1 and 10 \( \mu M \)) (24).

The only function demonstrated for Vrg4 in *S. cerevisiae* is the transport of GDP-Man. However, Lpg2 from *Leishmania major* is multifunctional and can transport GDP-arabinose and GDP-fucose in addition to GDP-Man (less efficiently in membrane assays in vitro) (25) but at comparable levels with reconstituted protein (24). While this was a unique finding at the time that it was initially observed, in recent years, multiple substrates have been demonstrated for several additional nucleotide sugar transporters (5, 9, 37, 40, 48, 50). To assess other potential substrates of the cryptococcal proteins, we performed GDP-[3H]Man transport assays in the presence of excess amounts of the nonradiolabeled compounds indicated in Table 2. While GDP and GDP-Man substantially reduced transport activity, the inhibitory effect of GDP-fucose was not statistically significant (\( P = 0.90 \) for Gmt1 and \( P = 0.66 \) for Gmt2 by \( Z \) test) (we did not test GDP-arabinose because it is not commercially available). This indicates that the transporter either does not transport this compound or does so with extremely low efficiency.

The two cryptococcal transporters are similar in terms of vrg4-2 complementation and in vitro transport characteristics. However, these studies were all performed in an exogenous system, so we next investigated the expression of these genes in *C. neoformans*. We performed quantitative reverse transcriptase PCR studies of wild-type cryptococcal cells cultured under three growth conditions by using either a rich medium that is
standard for laboratory growth or an LIM known to induce capsule production in vitro. Analysis of four independent RNA preparations for each condition showed that both genes were transcribed, although GMT1 transcripts were more abundant. The mean ratios of expression of GMT1 compared to that of GMT2 were 5.4 ± 0.3 for cells undergoing exponential growth in rich medium (YPD), 5.3 ± 1.2 for cells in stationary phase in YPD medium, and 7.9 ± 1.3 for cells undergoing exponential growth in LIM (see Materials and Methods).

To examine GMT1 and GMT2 expression in more detail, we performed microarray analysis to assess the expression of each gene under a variety of growth conditions (see Materials and Methods). The media that have been historically developed for C. neoformans culture are those that either alter capsule production or induce cell stress, so a selection of such conditions was used (see Materials and Methods). In most media tested, the expression of GMT1 exceeded that of GMT2 by several-fold, consistent with the results from the growth conditions tested by quantitative reverse transcriptase PCR. The ratio of expression of the two genes varied, ranging from 1 for samples grown in PBS to over 14 for samples grown in DMEM (data not shown).

We next examined the influence of environment on the regulation of GMT1 and GMT2 independently. To do this, we assessed the expression of each gene in our set of growth conditions relative to expression of the same gene in a reference pool of mixed RNA samples (see Materials and Methods). This experiment allowed us to draw several conclusions. First, the expression of both genes changed with growth conditions (Fig. 5). Second, under the conditions tested, GMT1 expression (Fig. 5, top panel) was fairly stable, exhibiting only a 3.5-fold difference overall. In contrast, GMT2 expression (Fig. 5, lower panel) was quite variable, with a range of over 17-fold. Finally, the two genes are not coordinately regulated. For example, GMT1 expression was decreased by over 40% relative to the reference pool in PBS, while expression of GMT2 was increased several-fold. Expression of these genes reversed during growth in low-thiamine Littman’s medium, where GMT1 expression was increased ~25%, while the expression of GMT2 was reduced by almost half.

Our expression studies suggested that Gmt1 and Gmt2 play different roles in the biology of Cryptococcus. To address this hypothesis, we replaced the gene encoding each transporter with a drug resistance marker and assessed the resulting disruption strains. Both mutants grew at the same rate as wild-type cells at 30°C (growth curves were performed as described in reference 47) (not shown). However, colonies of gmt1∆ cells appeared to be duller than those of the wild type, the gmt2∆ mutant, or the complemented gmt1∆ mutant (not shown). This feature is typical of cells with a reduced or absent capsule, a finding that intrigued us because of the extensive mannosylation of capsule polysaccharides.

To pursue the possibility that gmt1∆ cells had altered capsules, we used India ink staining and light microscopy to assess the capsule sizes of disruption and wild-type strains. Cells disrupted in GMT1 had smaller capsules than the wild type in the DMEM medium tested, with a radius of 0.67 ± 0.05 μm compared to 1.06 ± 0.06 μm (P value of <0.0001 by Student’s t test). We know that cryptococcal cells modulate capsule production in response to environment both in vitro and in vivo (26, 49, 58, 62), a process that is likely to be significant for pathogenesis. We therefore probed the mutant phenotype further by testing the response of gmt1∆ cells to growth in the same medium under a 5% CO2 atmosphere, a condition that leads to the formation of large capsules (62). When grown this way, the gmt1∆ mutant cells exhibited a striking defect in capsule formation (Fig. 6), which increased only slightly, to 0.94 ± 0.05 in radius compared to 3.29 ± 0.08 for the wild type.

### Table 2. Inhibition of GDP-[3H]Man transport

<table>
<thead>
<tr>
<th>Compound added</th>
<th>% Transport ± SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>100 ± 0</td>
</tr>
<tr>
<td>GDP-Man</td>
<td>12 ± 3</td>
</tr>
<tr>
<td>GDP-fucose</td>
<td>19 ± 5</td>
</tr>
<tr>
<td>GDP-glucosamine</td>
<td>83 ± 16</td>
</tr>
</tbody>
</table>

* All values were normalized to assays with no added inhibitor (100%). Average values and standard errors shown were calculated from the median values of six independent experiments.

* Nonradioactive compounds were present at a final concentration of 23 μM, a 230-fold molar excess over radiolabeled substrate.

---

**FIG. 5.** GMT1 and GMT2 are not coordinately expressed. Expression of each gene is plotted normalized to its expression in a reference pool (indicated by the dotted line). Values shown are the median values from three separate experiments using independently prepared RNA samples and performed in duplicate. The RNA samples indicated were prepared from JEC21 cells, which were grown overnight in the following media: YPD, LIM (low Fe), LIM without BPDS (low Fe − BPDS), DMEM, DMEM plus CO2, PBS, PBS plus fetal calf serum (FCS), Littman’s medium with 1 μg/ml thiamine (high thiamine), Littman’s medium with 0.01 μg/ml thiamine (low thiamine), YNB, YNB plus H2O2 (H2O2), or YNB plus NaNO2 (NaNO2). All cells were grown at 37°C except for YPD and YNB medium, which were grown at 30°C, and YNB medium with H2O2 or NaNO2, which was grown at 25°C. All growth was in room air, except the DMEM plus CO2 sample, which was grown in a 5% CO2 atmosphere. See Materials and Methods for additional details of growth media, preparation of the reference pool, and analysis.
highly conserved GDP-Man binding domains (17). They also have several basic residues in their C-terminal tails, a feature that has been implicated in recycling to the endoplasmic reticulum (2).

The presence of two GDP-Man transporters in *C. neoformans* is unique compared to the other fungi studied in this regard to date: *C. albicans*, *C. glabrata*, *P. pastoris*, and *S. cerevisiae*. Beyond yeast, several examples of multiple nucleotide sugar transporters with overlapping functions have been demonstrated. These include multiple UDP-galactose transporters described for plants (7), parasites (11a), and mammals (27, 61) and a set of five Golgi apparatus-localized proteins of *Arabidopsis thaliana* that all exhibit GDP-Man transport activity (8, 22).

One key question is whether Gmt1 and Gmt2 play different roles in the biology and pathogenesis of *C. neoformans*. Our expression data suggest that they do, because they demonstrate distinct patterns of regulation in response to growth conditions, despite similar biochemical characteristics. In particular, GMT1 is modestly regulated, with only a fewfold difference in expression under the growth conditions that we tested, while the expression of GMT2 is more dramatically modulated (Fig. 5). Furthermore, under all conditions but one, the magnitude of the observed changes in expression differed between the genes, and in several cases, these changes were in opposite directions.

Several of the growth conditions that we tested yielded cells with enlarged capsules, for example, growth in DMEM under CO$_2$ compared to growth in room air or growth in PBS with fetal calf serum as opposed to growth in PBS alone. However, we did not observe any correlation between the expression of either GMT gene and capsule size (not shown). This may be because the diverse conditions sampled here also affect the overall metabolic state of the cell and thus simultaneously alter the transport requirements for GDP-Man needed to synthesize other glycoconjugates.

Intrigued by the distinct expression patterns of two very similar genes, we deleted GMT1 and GMT2. Both deletion strains grow well in culture, but gmt1Δ cells demonstrate reduced capsule and a marked defect in capsule induction (Fig. 6), while gmt2 cells are wild type. This finding links GDP-Man transport and capsule synthesis, supporting our recent conclusion that capsule synthesis occurs inside subcellular organelles (60).

A further puzzle is how Gmt1 and Gmt2 could serve different biological functions while performing the same biochemical activity. It may be that these proteins are differentially localized, perhaps to serve distinct biosynthetic pathways. We know that localization is critical for the appropriate function of these proteins, because the *S. cerevisiae* protein Hvg1p, a close homolog of Vrg4 that is resident in the endoplasmic reticulum, cannot complement vrg4-2 cells unless it is engineered to reach the Golgi apparatus (18). In contrast, when the cryptococcal transporters are expressed in yeast, both are probably localized to the Golgi apparatus, since they do complement vrg4-2 cells.

It is possible that the two transporters occupy different regions of the Golgi apparatus in *C. neoformans*. A variety of proteins have been localized to subcompartments of the Golgi apparatus in mammalian systems (45), but current techniques do not allow sufficient resolution to examine protein localization...
within the smaller unstacked Golgi apparatus of Cryptococcus. Another possibility is that the two transporters associate with different synthetic machinery within the cell. In mammalian systems, there is precedent for the specific association of a nucleotide sugar transporter and a glycosyltransferase, which consumes the corresponding transport substrate (53).

Ultimately, distinguishing the biological roles of the proteins encoded by GMT1 and GMT2 will require detailed biochemical and morphological examinations of the two mutant strains to examine the effects of these mutations on other mannoserequiring processes and on cryptococcal virulence. The latter studies will be particularly important, since GDP-Man transporters are present in a variety of pathogens including fungi and parasites. Because the mammalian hosts of these organisms do not have such proteins, GDP-Man transporters have been suggested as potential targets of antimicrobial chemotherapy, a direction that merits further investigation.

ACKNOWLEDGMENTS

We thank members of the Doering Laboratory, Steve Beverley, and Sam Turco for stimulating discussions; Neta Dean for generosity in providing biological replicates and on Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxymannans with a computer-simulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146–159.


REFERENCES


